Understand the source comparison
IGF-1 LR3 Recovery Complete Guide 2026: Comparison Table
IGF-1 LR3 (40–60mcg post-training) Satellite cell proliferation via IGF-1R activation; sustained anabolic signaling 20–30hr half-life Measurable strength recovery improvement 48–96hr; cumulative hypertrophy effects 4–6 weeks Not FDA-approved for human use; req
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- IGF-1 LR3 (40–60mcg post-training)
- Satellite cell proliferation via IGF-1R activation; sustained anabolic signaling 20–30hr half-life
- Measurable strength recovery improvement 48–96hr; cumulative hypertrophy effects 4–6 weeks
- Not FDA-approved for human use; requires reconstitution and refrigerated storage; minimal effect on acute soreness
- Best-in-class for accelerating the satellite cell phase of recovery—backed by controlled mechanistic data but regulatory status limits accessibility
- Endogenous IGF-1 (post-meal or post-training spikes)
- Natural IGF-1 release via GH-insulin axis; short half-life (~10min) limits duration
- Transient MPS elevation 30–90min post-release; no sustained activation
- Rapid sequestration by IGFBPs; insufficient duration to maintain satellite cell proliferation through 48hr window
- Physiologically essential but temporally limited—cannot replicate the sustained receptor activation of exogenous LR3 analogue
- BPC-157 (250–500mcg/day)
- Promotes angiogenesis and collagen synthesis; modulates inflammatory cytokines
- Tendon/ligament repair improvements 7–14 days; anti-inflammatory effects within 48–72hr
- Primarily structural tissue repair—less direct effect on satellite cell activation or MPS; limited human clinical data
- Complementary to IGF-1 LR3 for connective tissue recovery but doesn't target the same myogenic pathways
- Creatine monohydrate (5g/day maintenance)
- ATP resynthesis; cell volumisation increases satellite cell signaling
- Performance restoration 24–48hr; hypertrophy contribution over 8–12 weeks
- Indirect recovery mechanism—improves training capacity rather than repair kinetics directly
- Evidence-based and cost-effective but mechanistically downstream from IGF-1 signaling—works synergistically rather than redundantly
- Leucine threshold dosing (2.5–3g per meal)
- Activates mTORC1 pathway; initiates muscle protein synthesis
- MPS elevation 60–120min post-ingestion; returns to baseline within 3–4hr
- Requires per-meal distribution; total daily protein matters more than leucine alone; no effect on satellite cell proliferation independent of training
- Foundational nutrition strategy but doesn't extend satellite cell activation window the way IGF-1 LR3 does